DRUG
Price
$33.42
Change
-$0.68 (-1.99%)
Updated
Apr 24 closing price
Capitalization
241.49M
IVA
Price
$3.77
Change
-$0.14 (-3.58%)
Updated
Apr 24 closing price
Capitalization
349.63M
28 days until earnings call
Ad is loading...

DRUG vs IVA

Header iconDRUG vs IVA Comparison
Open Charts DRUG vs IVABanner chart's image
Bright Minds Biosciences
Price$33.42
Change-$0.68 (-1.99%)
Volume$23.84K
Capitalization241.49M
Inventiva SA
Price$3.77
Change-$0.14 (-3.58%)
Volume$10.57K
Capitalization349.63M
DRUG vs IVA Comparison Chart
Loading...
DRUG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DRUG vs. IVA commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DRUG is a StrongBuy and IVA is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (DRUG: $33.42 vs. IVA: $3.77)
Brand notoriety: DRUG and IVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DRUG: 61% vs. IVA: 65%
Market capitalization -- DRUG: $241.49M vs. IVA: $349.63M
DRUG [@Biotechnology] is valued at $241.49M. IVA’s [@Biotechnology] market capitalization is $349.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DRUG’s FA Score shows that 0 FA rating(s) are green whileIVA’s FA Score has 0 green FA rating(s).

  • DRUG’s FA Score: 0 green, 5 red.
  • IVA’s FA Score: 0 green, 5 red.
According to our system of comparison, IVA is a better buy in the long-term than DRUG.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DRUG’s TA Score shows that 6 TA indicator(s) are bullish while IVA’s TA Score has 4 bullish TA indicator(s).

  • DRUG’s TA Score: 6 bullish, 3 bearish.
  • IVA’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, DRUG is a better buy in the short-term than IVA.

Price Growth

DRUG (@Biotechnology) experienced а +0.94% price change this week, while IVA (@Biotechnology) price change was +12.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

DRUG is expected to report earnings on Aug 28, 2023.

IVA is expected to report earnings on Sep 25, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IVA($350M) has a higher market cap than DRUG($241M). IVA YTD gains are higher at: 76.168 vs. DRUG (-7.218).
DRUGIVADRUG / IVA
Capitalization241M350M69%
EBITDA-2.67MN/A-
Gain YTD-7.21876.168-9%
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash57.9MN/A-
Total Debt183KN/A-
TECHNICAL ANALYSIS
Technical Analysis
DRUGIVA
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
74%
Declines
ODDS (%)
Bearish Trend 9 days ago
88%
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
View a ticker or compare two or three
Ad is loading...
DRUG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JFAMX30.21N/A
N/A
JPMorgan Emerging Markets Equity A
LMREX28.38N/A
N/A
ClearBridge Mid Cap R
CBSYX15.27N/A
N/A
AB Global Risk Allocation Adv
SWSCX16.77N/A
N/A
Schwab Small-Cap Equity
NSFFX10.92N/A
N/A
Natixis Target Retirement 2030 N